Kenvue
Kenvue Inc. (NYSE: KVUE) is a global consumer health company selling over-the-counter medicines and personal care products to consumers in more than 165 countries. Its portfolio spans three reportable segments: Self Care, including cough, cold, allergy, pain, digestive health, smoking cessation and eye care; Skin… From the company’s description.
In fiscal 2025, Kenvue reported revenue of $15.12B, down 2.1% from fiscal 2024, and net income of $1.47B. Its operating margin was 16.0%, and operations generated $2.20B in cash. Over the twelve months to Jun 28, 2026, revenue was $15.41B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Kenvue does
In the company’s own words
Kenvue Inc. (NYSE: KVUE) is a global consumer health company selling over-the-counter medicines and personal care products to consumers in more than 165 countries. Its portfolio spans three reportable segments: Self Care, including cough, cold, allergy, pain, digestive health, smoking cessation and eye care; Skin Health and Beauty, including face and body care, hair and sun care; and Essential Health, including oral, baby, wound and menstrual care. Major brands include Tylenol, Zyrtec, Nicorette, Aveeno, Neutrogena, BAND-AID Brand, Listerine and Johnson’s. Kenvue’s products are sold through retail and online channels, and the company also offers connected health services such as digital diagnostics and telemedicine. It develops and manufactures products using a global workforce and a combination of in-house factories and third-party suppliers. Kenvue reports $15.1 billion in net sales for fiscal 2025 and approximately 22,000 employees as of December 28, 2025. The company was formed from Johnson & Johnson’s Consumer Health business and became independent in 2023. Its website is https://www.kenvue.com.
Company details
- Sector
- Consumer Staples
- Industry (SIC)
- Personal Care
- Headquarters
- SUMMIT, NJ
- Fiscal year end
- January
- CIK
- 1944048
- SIC
- 2844
Financial performance, year by year
Fiscal 2023–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Kenvue — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Kenvue · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Kenvue’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Kenvue’s bonds, as funds hold them
Funds report holding 7 issues of Kenvue’s debt, $998.76M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.98%, maturing 2028 to 2063.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Kenvue and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Kenvue's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Kenvue's last four quarterly filings that the numbers alone won't show?”